Bioequivalence Study of Favir 200 mg Film Tablet Kocak Under Fasting Conditions
NCT ID: NCT04444986
Last Updated: 2020-11-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
2020-06-05
2020-06-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FAVIR then AVIGAN
Participants first received Favir 200 mg FT manufactured by Kocak in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
FAVIR 200 MG FT
FAVICOVIR containing 200 mg favipiravir manufactured by Kocak, Turkey.
AVIGAN 200 mg FT
AVIGAN containing 200 mg favipiravir manufactured by Toyama, Japan
AVIGAN then FAVIR
Participants first received Favir 200 mg FT manufactured by Kocak in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
FAVIR 200 MG FT
FAVICOVIR containing 200 mg favipiravir manufactured by Kocak, Turkey.
AVIGAN 200 mg FT
AVIGAN containing 200 mg favipiravir manufactured by Toyama, Japan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FAVIR 200 MG FT
FAVICOVIR containing 200 mg favipiravir manufactured by Kocak, Turkey.
AVIGAN 200 mg FT
AVIGAN containing 200 mg favipiravir manufactured by Toyama, Japan
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Non smokers or smoking maximum 5 cigarettes a day, those who won't smoke or drink coffee during the study period,
3. Two Negative Covid-19 PCR test results.
4. Negative alcohol breath test results,
5. Normal physical examination at screening visit,
6. Having the Body Mass Index ranged between 18.5-30 kg/m2 (see Appendix I) which is in the desirable range according to the age,
7. Ability to communicate adequately with the investigator himself or his representatives,
8. Ability and agreement to comply with the study requirements,
9. Normal blood pressure and heart rate measured under stabilised conditions at the screening visit after at least 5 minutes of rest under supine position: SBP within 100 to 140 mmHg, DBP within 60 to 90 mmHg and HR within 50 to 90 bpm,
10. Normal/ acceptable 12-lead electrocardiographic results at least after 5 minutes of rest,
11. Laboratory results within normal range or clinically non-significant (CBC, glucose, urea, uric acid, creatinine, estimated GFR (eGFR), total bilirubin, sodium, potassium, calcium, chloride, SGOT (AST), SGPT (ALT), GGT, alkaline phosphatase, total protein and urinalysis), drug addiction scanning in urine results in negative (amphetamine, barbiturate, benzodiazepine, cannabinoid, cocaine, opiate),
12. Understanding of the study and agreement to give a written informed consent according to section 20.3.
13. Understanding of that he and his partner will use a practice adequate contraception during the study and at least 7 days after the study.
19. History of difficulty of swallowing.
20. Intake of depot injectable solutions (including study medications) within 6 months before start of the study.
21. Intake of enzyme-inducing, organotoxic or long half-life drugs within 4 weeks before start of the study.
22. Special diet due to any reason, e.g. vegetarian.
Exclusion Criteria
2. Who have positive Covid-19 PCR test result.
3. Any history or presence of clinical relevance of cardiovascular, neurological, musculoskeletal, haematological, hepatic, gastrointestinal, renal, pulmonary, endocrinological, metabolism or psychiatric disease, any type of porphyria.
4. Symptomatic or asymptomatic orthostatic hypotension at screening or before the first drug administration defined by a decrease of SBP more than 20 mmHg or DBD more than 10 mmHg occurs between sitting/supine to standing position subject will be excluded (if it deemed necessary by the investigator),
5. Presence or history of malabsorption or any gastrointestinal surgery except appendectomy or except herniotomy.
6. Subjects who have given more than 400 mL blood within the last two months before the first drug administration and subjects who have participated to any drug research within the last two months before the first drug administration.
7. Subjects suspected to have a high probability of non-compliance to the study procedure and/or completion of the study according to the investigator's judgement.
8. Subjects who used any of prescribed systemic or topical medication (including OTC medication) within 2 weeks (or six elimination half lives of this medication, whichever is longer) before the initiation of the study (except single doses of analgesics which have no drug interaction with study product).
9. Use of any vitamins or herbal products within 7 days prior to the initial dose of the study medication.
10. History of allergic response to heparin.
11. Subjects who have any chronic disease which might interfere with absorption, distribution, metabolism or excretion of the drug.
12. Subjects who regular consumed of beverages or food containing methylxanthines (e.g. coffee, tea, cola, caffeine, chocolate, sodas,) equivalent to more than 500 mg methylxanthines per day.
13. Subjects who has taken any grapefruit or grapefruit juice during 7 days prior to drug administration, during the study.
14. History of drug abuse.
15. History of alcohol abuse and/or regular use of more than 2 units of alcohol per day or 10 units per week and/or positive alcohol breath test results (Note: one unit of alcohol equals 250 mL beer, 125 mL wine or 25 mL spirits).
16. Positive blood test for HBV, HCV and HIV.
17. Who have relationship to the investigator.
18 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novagenix Bioanalytical Drug R&D Center
NETWORK
Farmagen Ar-Ge Biyot. Ltd. Sti
NETWORK
Kocak Farma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Muradiye Nacak, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Farmagen Ar-Ge Biyot. Ltd. Sti
Taner Ezgi, MD
Role: STUDY_CHAIR
Farmagen Ar-Ge Biyot. Ltd. Sti
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novagenix Drug R&D Center
Akyurt, Ankara, Turkey (Türkiye)
Farmagen Ar-Ge Biyot. Ltd. Sti.
Gaziantep, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol, Statistical Analysis Plan, and Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NOV2020/01919
Identifier Type: -
Identifier Source: org_study_id